

List of Progress in Hematology "Review Series" 2023-2024

2024

Acute myeloid Leukemia: Recent progress in AML with recurrent genetic abnormalities and Molecular targeted therapy (Edited by Yuichi Ishikawa)

1. Ishikawa Y. Recent progress in AML with recurrent genetic abnormalities Int J Hematol. 2024;120:525–7.
<https://link.springer.com/article/10.1007/s12185-024-03848-3>
2. Kennedy VE, Smith CC. FLT3 targeting in the modern era: from clonal selection to combination therapies Int J Hematol. 2024;120:528–40.
<https://link.springer.com/article/10.1007/s12185-023-03681-0>
3. Tien F, Hou H. CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment Int J Hematol. 2024;120:541–7.
<https://link.springer.com/article/10.1007/s12185-024-03773-5>
4. Yokoyama Y. Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia Int J Hematol. 2024;120:548–55.
<https://link.springer.com/article/10.1007/s12185-023-03696-7>
5. Ishikawa Y, Ushijima Y, Kiyoi H. Recent advances in AML with mutated NPM1 Int J Hematol. 2024;120:556–65.
<https://link.springer.com/article/10.1007/s12185-024-03835-8>

Recent progress in the molecular pathophysiology and treatment of acute myeloid leukemia (Edited by Hiroki Yamaguchi)

1. Yamaguchi H. Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia Int J Hematol. 2024;120:414–6.
<https://link.springer.com/article/10.1007/s12185-024-03837-6>
2. Nagata Y. Molecular pathophysiology of germline mutations in acute myeloid leukemia Int J Hematol. 2024;120:417–26.
<https://link.springer.com/article/10.1007/s12185-024-03824-x>
3. Shi X, Feng M, Nakada D. Metabolic dependencies of acute myeloid leukemia stem cells Int J Hematol. 2024;120:427–38.
<https://link.springer.com/article/10.1007/s12185-024-03789-x>
4. Urrutia S, Takahashi K. Precision medicine in AML: overcoming resistance Int J Hematol. 2024;120:439–54.
<https://link.springer.com/article/10.1007/s12185-024-03827-8>
5. Saito S, Nakazawa Y. CAR-T cell therapy in AML: recent progress and future perspectives Int J Hematol. 2024;120:455–66.
<https://link.springer.com/article/10.1007/s12185-024-03809-w>

Novel treatment strategies for hematological malignancies in the era of immune therapy (Edited by Yoichi Imai)

1. Imai Y. Novel treatment strategies for hematological malignancies in the immunotherapy era Int J Hematol. 2024;120:3–5.
<https://link.springer.com/article/10.1007/s12185-024-03793-1>
2. Goto H, Onozawa M, Teshima T. Novel CAR T cell therapies for patients with large B cell lymphoma Int J Hematol. 2024;120:6–14.

<https://link.springer.com/article/10.1007/s12185-024-03792-2>

3. Nakashima T, Kagoya Y. Current progress of CAR-T-cell therapy for patients with multiple myeloma Int J Hematol. 2024;120:15–22.
<https://link.springer.com/article/10.1007/s12185-024-03794-0>
4. Ochi T, Konishi T, Takenaka K. Bispecific antibodies for multiple myeloma: past, present and future Int J Hematol. 2024;120:23–33.
<https://link.springer.com/article/10.1007/s12185-024-03766-4>
5. Kaito Y, Imai Y. Evolution of natural killer cell-targeted therapy for acute myeloid leukemia Int J Hematol. 2024;120:34–43.
<https://link.springer.com/article/10.1007/s12185-024-03778-0>

Cancer associated thrombosis and bleeding (Edited by Takayuki Ikezoe)

1. Ikezoe T. Cancer-associated thrombosis and bleeding Int J Hematol. 2024;119:493–4.
<https://link.springer.com/article/10.1007/s12185-024-03716-0>
2. Tatsumi K. The pathogenesis of cancer-associated thrombosis Int J Hematol. 2024;119:495–504.
<https://link.springer.com/article/10.1007/s12185-024-03735-x>
3. Seki Y. Clinical guidelines for prevention and treatment of CAT in Japan and other countries Int J Hematol. 2024;119:505–15.
<https://link.springer.com/article/10.1007/s12185-024-03736-w>

4. Fukatsu M, Ikezoe T. Cancer-associated thrombosis in hematologic malignancies Int J Hematol. 2024;119:516–25.
<https://link.springer.com/article/10.1007/s12185-023-03690-z>
5. Hisada Y. Dysregulated hemostasis in acute promyelocytic leukemia Int J Hematol. 2024;119:526–31.
<https://link.springer.com/article/10.1007/s12185-024-03708-0>

Aplastic anemia (Edited by Yasushi Onishi)

1. Onishi Y. Aplastic anemia: history and recent developments in diagnosis and treatment Int J Hematol. 2024;119:217–9.
<https://link.springer.com/article/10.1007/s12185-024-03715-1>
2. Storb R. Allogeneic bone marrow transplantation for aplastic anemia Int J Hematol. 2024;119:220–30.
<https://link.springer.com/article/10.1007/s12185-022-03506-6>
3. Nakao S. Diagnosis of immune pathophysiology in patients with bone marrow failure Int J Hematol. 2024;119:231–9.
<https://link.springer.com/article/10.1007/s12185-022-03519-1>
4. Yoshida N. Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia Int J Hematol. 2024;119:240–7.
<https://link.springer.com/article/10.1007/s12185-023-03564-4>
5. Scheinberg P. Progress in medical therapy in aplastic anemia: why it took so long? Int J Hematol. 2024;119:248–54.
<https://link.springer.com/article/10.1007/s12185-024-03713-3>

2023

Prophylactic or pre-emptive therapies to prevent relapse after allogeneic stem cell transplantation (Edited by Shinichi Kako)

1. Kako S. Prophylactic or pre-emptive therapies to prevent relapse after allogeneic hematopoietic stem cell transplantation Int J Hematol. 2023;118:155–7.
<https://link.springer.com/article/10.1007/s12185-023-03631-w>
2. Harada K. Pre-emptive and prophylactic donor lymphocyte infusion following allogeneic stem cell transplantation Int J Hematol. 2023;118: 158–68.
<https://link.springer.com/article/10.1007/s12185-023-03595-x>
3. Najima Y. Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS Int J Hematol. 2023;118:169–82.
<https://link.springer.com/article/10.1007/s12185-023-03596-w>
4. Nakasone H. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia Int J Hematol. 2023;118:183–92.
<https://link.springer.com/article/10.1007/s12185-023-03556-4>
5. Kawamura K. Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma Int J Hematol. 2023;118:193–200.
<https://link.springer.com/article/10.1007/s12185-023-03602-1>

Stem cell regulation and dynamics in myeloid malignancies (Edited by Goro Sashida)

1. Sashida G. Stem cell regulation and dynamics in myeloid malignancies Int J Hematol. 2023;117:789–90.
<https://link.springer.com/article/10.1007/s12185-023-03615-w>
2. Yang F, Agosto-Peña J. Epigenetic regulation by ASXL1 in myeloid malignancies Int J Hematol. 2023;117:791–806.
<https://link.springer.com/article/10.1007/s12185-023-03586-y>
3. Jin Z, MacPherson K, Liu Z, Vu LP.. RNA modifications in hematological malignancies Int J Hematol. 2023;117:807–20.
<https://link.springer.com/article/10.1007/s12185-023-03576-0>
4. Hayashi Y, Nishimura K, Tanaka A, Inoue D. Extracellular vesicle-mediated remodeling of the bone marrow microenvironment in myeloid malignancies Int J Hematol. 2023;117:821–9.
<https://link.springer.com/article/10.1007/s12185-023-03587-x>
5. Abdallah MG, Teoh VSI, Dutta B, Yokomizo T, Osato M. Childhood hematopoietic stem cells constitute the permissive window for RUNX1-ETO leukemogenesis Int J Hematol. 2023;117:830–8.
<https://link.springer.com/article/10.1007/s12185-023-03605-y>

Immunotherapy: Cancer immunotherapy development: From a different perspective (Edited by Hideto Tamura)

1. Tamura H. Guest Editorial: what can be done to improve cancer immunotherapies? Int J Hematol. 2023;117:631–3.
<https://link.springer.com/article/10.1007/s12185-023-03578-y>
2. Gicobi JK. Resilient T-cell responses in patients with advanced cancers Int J Hematol. 2023;117:634–9.

<https://link.springer.com/article/10.1007/s12185-022-03424-7>

3. Yamamoto T. Extracellular vesicle-mediated immunoregulation in cancer Int J Hematol. 2023;117:640–6.
<https://link.springer.com/article/10.1007/s12185-022-03436-3>
4. Ohta K, Sakoda Y, Tamada K. Novel technologies for improving the safety and efficacy of CAR-T cell therapy Int J Hematol. 2023;117:647–51.
<https://link.springer.com/article/10.1007/s12185-022-03478-7>
5. Russell BM, Avigan DE. Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy Int J Hematol. 2023;117:652–9.
<https://link.springer.com/article/10.1007/s12185-023-03579-x>

T-cell lymphoma (Edited by Kenji Ishitsuka)

1. Ishitsuka K. T cell lymphoma: time to make discoveries and advance treatment Int J Hematol. 2023;117:473–4.
<https://link.springer.com/article/10.1007/s12185-023-03573-3>
2. Lewis NE, Sardana R, Dogan A. Mature T-cell and NK-cell lymphomas: updates on molecular genetic features Int J Hematol. 2023;117:475–91.
<https://link.springer.com/article/10.1007/s12185-023-03537-7>
3. Stuver R, Lewis N, Dogan A, Horwitz SM. Moving towards biologically informed treatment strategies for T-cell lymphomas Int J Hematol. 2023;117:492–503.

<https://link.springer.com/article/10.1007/s12185-022-03524-4>

4. Yasunaga J. Viral, genetic, and immune factors in the oncogenesis of adult T-cell leukemia/lymphoma Int J Hematol. 2023;117:504–11.
<https://link.springer.com/article/10.1007/s12185-023-03547-5>
5. Katsuya H. Current and emerging therapeutic strategies in adult T-cell leukemia–lymphoma Int J Hematol. 2023;117:512–22.
<https://link.springer.com/article/10.1007/s12185-023-03572-4>

Progress in pathophysiology and treatment of thrombocytopenia (Edited by Hirokazu Kashiwagi)

1. Kashiwagi H. Progress in pathophysiological understanding and treatment of thrombocytopenia Int J Hematol. 2023;117:314–5.
<https://link.springer.com/article/10.1007/s12185-023-03542-w>
2. Rodeghiero F. Recent progress in ITP treatment Int J Hematol. 2023;117:316–30.
<https://link.springer.com/article/10.1007/s12185-022-03527-1>
3. Kubo M, Matsumoto M. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura Int J Hematol. 2023;117:331–40.
<https://link.springer.com/article/10.1007/s12185-023-03552-8>
4. Venier LM, Clerici B, Bissola AL, Modi D, Jevtic SD, Radford M, et al. Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder Int J Hematol. 2023;117:341–8.
<https://link.springer.com/article/10.1007/s12185-022-03516-4>

5. Chen S, Sugimoto N, Eto K. Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets Int J Hematol. 2023;117:349–55.
<https://link.springer.com/article/10.1007/s12185-022-03512-8>

Recent progress in pediatric leukemia (Edited by Toshihiko Imamura)

1. Imamura T. Guest editorial: recent progress in pediatric leukemia Int J Hematol. 2023;117:153–4.
<https://link.springer.com/article/10.1007/s12185-023-03536-8>
2. Kato M. Recent progress in pediatric lymphoblastic leukemia Int J Hematol. 2023;117:155–61.
<https://link.springer.com/article/10.1007/s12185-022-03501-x>
3. Tomizawa D. Evolution and optimization of therapies for acute lymphoblastic leukemia in infants Int J Hematol. 2023;117:162–72.
<https://link.springer.com/article/10.1007/s12185-022-03502-w>
4. Shiba N. Comprehensive molecular understanding of pediatric acute myeloid leukemia Int J Hematol. 2023;117:173–81.
<https://link.springer.com/article/10.1007/s12185-023-03533-x>
5. Shima H, Shimada H. Recent progress in the management of pediatric chronic myeloid leukemia Int J Hematol. 2023;117:182–7.
<https://link.springer.com/article/10.1007/s12185-022-03526-2>

Chronic myeloid leukemia: the cutting-edge evidence and things we should know (Edited by Noriyoshi Iriyama)

1. Iriyama N. Chronic myeloid leukemia: the cutting-edge evidence and things we should know Int J Hematol. 2023;117:1-2.
<https://link.springer.com/article/10.1007/s12185-022-03511-9>
2. Özdemir ZN, Kılıçaslan NA, Yılmaz M. Eşkazan AE. Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities Int J Hematol. 2023;117:3-15.
<https://link.springer.com/article/10.1007/s12185-022-03446-1>
3. Laganà A, Scalzulli E, Carmosino I, Martelli M, Breccia M. Asciminib as a third line option in chronic myeloid leukemia Int J Hematol. 2023;117:16-23.
<https://link.springer.com/article/10.1007/s12185-022-03432-7>
4. Umezawa Y, Sasaki K. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia Int J Hematol. 2023;117:24-9.
<https://link.springer.com/article/10.1007/s12185-022-03431-8>
5. Ochi, Y. Genetic landscape of chronic myeloid leukemia Int J Hematol. 2023;117:30-6.
<https://link.springer.com/article/10.1007/s12185-022-03510-w>